Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Non-Coding Rnas in Cancer Immunotherapy: A Solution to Overcome Immune Resistance? Publisher



Afra F1 ; Eftekhar SP2 ; Farid AS3 ; Ala M4
Authors

Source: Progress in Molecular Biology and Translational Science Published:2024


Abstract

With the rapid advancement in immunotherapy, cancer immune resistance has become more evident, which demands new treatment approaches to achieve greater efficacy. Non-coding RNAs (ncRNAs) are a heterogeneous group of RNAs that are not translated to proteins but instead regulate different stages of gene expression. Recent studies have increasingly supported the critical role of ncRNAs in immune cell-cancer cell cross-talk, and numerous ncRNAs have been implicated in the immune evasion of cancer cells. Cancer cells take advantage of ncRNAs to modulate several signaling pathways and upregulate the expression of immune checkpoints and anti-inflammatory mediators, thereby dampening the anti-tumor response of M1 macrophages, dendritic cells, cytotoxic T cells, and natural killer cells or potentiating the immunosuppressive properties of M2 macrophages, regulatory T cells, and myeloid-derived suppressive cells. Upregulation of immunosuppressive ncRNAs or downregulation of immunogenic ncNRAs is a major driver of resistance to immune checkpoint inhibitors, cancer vaccines, and other means of cancer immunotherapy, making ncRNAs ideal targets for treatment. In addition, ncRNAs released by cancer cells have been demonstrated to possess prognostic values for patients who undergo cancer immunotherapy. Future clinical trials are urged to consider the potential of ncRNAs in cancer immunotherapy. © 2024
Related Docs
View other Related Docs
1. Recent Progress in the Immunotherapy of Hepatocellular Carcinoma: Non-Coding Rna-Based Immunotherapy May Improve the Outcome, Biomedicine and Pharmacotherapy (2023)
2. Noncoding Ribonucleic Acids (Rnas) May Improve Response to Immunotherapy in Pancreatic Cancer, ACS Pharmacology and Translational Science (2024)
3. Prospect of Exosomal Circular Rnas in Breast Cancer: Presents and Future, Molecular Biology Reports (2022)
Experts (# of related papers)
View all Related Experts
Mohammad Vaezi (1)
Nima Rezaei (1)
Other Related Docs
4. The Landscape of Exosomal Non-Coding Rnas in Breast Cancer Drug Resistance, Focusing on Underlying Molecular Mechanisms, Frontiers in Pharmacology (2023)
5. Non-Coding Rnas in Leukemia Drug Resistance: New Perspectives on Molecular Mechanisms and Signaling Pathways, Annals of Hematology (2024)
6. The Immunobiology of Myeloid-Derived Suppressor Cells in Cancer, Tumor Biology (2016)
7. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
8. How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer, International Immunopharmacology (2020)
9. Exosomal Long Non-Coding Rnas: Novel Molecules in Gastrointestinal Cancers’ Progression and Diagnosis, Frontiers in Oncology (2022)
10. Constructing Mrna, Mirna, Circrna and Lncrna Regulatory Network by Analysis of Microarray Data in Breast Cancer, Gene Reports (2022)
11. Melatonin Targeting Non-Coding Rnas in Cancer: Focus on Mechanisms and Potential Therapeutic Targets, European Journal of Pharmacology (2023)
12. Circular Rnas: New Genetic Tools in Melanoma, Biomarkers in Medicine (2020)
13. Non-Coding Rnas As Potential Therapeutic Targets for Receptor Tyrosine Kinase Signaling in Solid Tumors: Current Status and Future Directions, Cancer Cell International (2024)
14. Immune Checkpoints and Ncrnas: Pioneering Immunotherapy Approaches for Hematological Malignancies, Cancer Cell International (2024)
15. Peaceful Existence of Tumor Cells With Their Non-Malignant Neighbors: The Trade of Tumor Cells With Tumor Micro-Environment, Current Chemical Biology (2020)
16. Circular Rnas (Circrnas) in Cancer Proliferation: Molecular Interactions and Possible Therapeutic Targets, Non-coding RNA Transcripts In Cancer Therapy: Pre-clinical And Clinical Implications (2023)
17. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)
18. Competing Endogenous Rnas Regulatory Crosstalk Networks: The Messages From the Rna World to Signaling Pathways Directing Cancer Stem Cell Development, Heliyon (2024)
19. The Effects of Exercise on Epigenetic Modifications: Focus on Dna Methylation, Histone Modifications and Non-Coding Rnas, Human Cell (2024)
20. The Role of Non-Coding Rnas in the Regulation of Cell Death Pathways in Melanoma, Discover Oncology (2025)